Fig. 1: Epcoritamab mediates comparable levels of cytotoxicity in various B-NHL subtypes and in ND and RR samples, including samples from patients who received prior CD20-antibody containing treatment. | Blood Cancer Journal

Fig. 1: Epcoritamab mediates comparable levels of cytotoxicity in various B-NHL subtypes and in ND and RR samples, including samples from patients who received prior CD20-antibody containing treatment.

From: Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

Fig. 1

A Percentages cytotoxicity mediated by epcoritamab and CD3xCtrl (30 ng/mL) and B EC50 values (ng/mL), shown for samples with clear dose-response curves, for cytotoxicity in the presence of allogeneic PBMCs (E:T ratio 10:1) in ND and RR DLBCL (n = 16), FL (n = 15), and MCL (n = 8) samples (median ± interquartile range), including patients who relapsed from or were refractory to CD20 therapy ( and , respectively). Statistical analysis was performed with Kruskal–Wallis and Dunn’s multiple comparisons test to compare epcoritamab with CD3xCtrl for each indication (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001) and epcoritamab-dependent cytotoxicity between subtypes (ns (C) CD20 expression (antibody molecules per cell) on tumor cells in samples from B-NHL patients unexposed to prior CD20 therapy correlated to epcoritamab-dependent cytotoxicity (30 ng/mL) (Spearman’s; ns). D Time between last CD20-therapy and moment of lymph node biopsy (months) of patients previously treated with CD20-antibody containing treatment (n = 8) correlated to cytotoxicity mediated by epcoritamab (30 ng/mL) (Spearman’s; r = 0.78, *p = 0.03).

Back to article page